ASH 2023: MRD Highlights in BioPharma Drug Development

Read More

IL-32γ potentiates tumor immunity in melanoma

Gruber T., et al.
JCI Insight
September 2020
Authors and Affiliates
Thomas Gruber 1,2, Mirela Kremenovic 1,2, Hassan Sadozai 1,2, Nives Rombini 1, Lukas Baeriswyl 1, Fabienne Maibach 1, Robert L Modlin 3, Michel Gilliet 4, Diego von Werdt 1,2, Robert E Hunger 5, S Morteza Seyed Jafari 5, Giulia Parisi 6, Gabriel Abril-Rodriguez 6, Antoni Ribas 6, Mirjam Schenk 1; 1 Institute of Pathology, Experimental Pathology, and. 2 Graduate School Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. 3 Division of Dermatology, Department of Medicine and Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. 4 Department of Dermatology, Lausanne University Hospital, Lausanne, Switzerland. 5 Department of Dermatology, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland. 6 Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, and UCLA Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA.